These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15762277)

  • 1. A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening andtreatment.
    Hansel DE; Ashfaq R; Rahman A; Wanzer D; Yeo CJ; Wilentz RE; Maitra A
    Am J Clin Pathol; 2005 Jan; 123(1):28-35. PubMed ID: 15762277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
    Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
    Hicks DG; Yoder BJ; Pettay J; Swain E; Tarr S; Hartke M; Skacel M; Crowe JP; Budd GT; Tubbs RR
    Hum Pathol; 2005 Apr; 36(4):348-56. PubMed ID: 15891995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
    Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
    Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
    Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
    Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
    Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
    Mueller RE; Parkes RK; Andrulis I; O'Malley FP
    Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2/neu expression and gene alterations in pancreatic ductal adenocarcinoma: a comparative immunohistochemistry and chromogenic in situ hybridization study based on tissue microarrays and computerized image analysis.
    Tsiambas E; Karameris A; Dervenis C; Lazaris AC; Giannakou N; Gerontopoulos K; Patsouris E
    JOP; 2006 May; 7(3):283-94. PubMed ID: 16685109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
    Villman K; Sjöström J; Heikkilä R; Hultborn R; Malmström P; Bengtsson NO; Söderberg M; Saksela E; Blomqvist C
    Acta Oncol; 2006; 45(5):590-6. PubMed ID: 16864174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased topoisomerase IIalpha expression in colorectal cancer is associated with advanced disease and chemotherapeutic resistance via inhibition of apoptosis.
    Coss A; Tosetto M; Fox EJ; Sapetto-Rebow B; Gorman S; Kennedy BN; Lloyd AT; Hyland JM; O'Donoghue DP; Sheahan K; Leahy DT; Mulcahy HE; O'Sullivan JN
    Cancer Lett; 2009 Apr; 276(2):228-38. PubMed ID: 19111388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer.
    Konecny GE; Pauletti G; Untch M; Wang HJ; Möbus V; Kuhn W; Thomssen C; Harbeck N; Wang L; Apple S; Jänicke F; Slamon DJ
    Breast Cancer Res Treat; 2010 Apr; 120(2):481-9. PubMed ID: 20130985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
    Jacobson KK; Morrison LE; Henderson BT; Blondin BA; Wilber KA; Legator MS; O'Hare A; Van Stedum SC; Proffitt JH; Seelig SA; Coon JS
    Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
    Järvinen TA; Tanner M; Bärlund M; Borg A; Isola J
    Genes Chromosomes Cancer; 1999 Oct; 26(2):142-50. PubMed ID: 10469452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.
    Coon JS; Marcus E; Gupta-Burt S; Seelig S; Jacobson K; Chen S; Renta V; Fronda G; Preisler HD
    Clin Cancer Res; 2002 Apr; 8(4):1061-7. PubMed ID: 11948114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.
    Hagen AI; Bofin AM; Ytterhus B; Maehle LO; Kjellevold KH; Myhre HO; Møller P; Lønning PE
    Acta Oncol; 2007; 46(2):199-203. PubMed ID: 17453369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification.
    Vranic S; Frkovic-Grazio S; Lamovec J; Serdarevic F; Gurjeva O; Palazzo J; Bilalovic N; Lee LM; Gatalica Z
    Hum Pathol; 2010 Nov; 41(11):1617-23. PubMed ID: 20688355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
    Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
    J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.